Insulet Corp. (NASDAQ: PODD) Stock Competitors & Peer Comparison
See PODD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PODD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PODD | $140.60 | -0.67% | 9.7B | 23.95 | $5.87 | N/A |
| ABT | $102.61 | +0.37% | 177.4B | 19.68 | $5.21 | +2.42% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $92.13 | -0.69% | 118B | 16.66 | $5.53 | +3.08% |
| SYK | $275.12 | -1.79% | 105.4B | 20.54 | $13.39 | +1.26% |
| BSX | $43.34 | -0.48% | 64.5B | 14.00 | $3.10 | N/A |
| EW | $88.26 | +0.01% | 50.8B | 32.69 | $2.70 | N/A |
| DXCM | $89.35 | +1.61% | 33.7B | 35.04 | $2.55 | N/A |
| GEHC | $64.13 | -0.49% | 29B | 14.06 | $4.56 | +0.22% |
| PHG | $24.68 | +0.00% | 24.1B | 14.10 | $1.75 | +4.01% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
PODD vs ABT Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, ABT has a market cap of 177.4B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while ABT trades at $102.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas ABT's P/E ratio is 19.68. In terms of profitability, PODD's ROE is +0.27%, compared to ABT's ROE of +0.11%. Regarding short-term risk, PODD is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for PODD.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
PODD vs BSX-PA Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, PODD's ROE is +0.27%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, PODD is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for PODD.Check BSX-PA's competition here
Medtronic plc (NYSE: MDT)
PODD vs MDT Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, MDT has a market cap of 118B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while MDT trades at $92.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas MDT's P/E ratio is 16.66. In terms of profitability, PODD's ROE is +0.27%, compared to MDT's ROE of +0.11%. Regarding short-term risk, PODD is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for PODD.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
PODD vs SYK Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, SYK has a market cap of 105.4B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while SYK trades at $275.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas SYK's P/E ratio is 20.54. In terms of profitability, PODD's ROE is +0.27%, compared to SYK's ROE of +0.16%. Regarding short-term risk, PODD is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for PODD.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
PODD vs BSX Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, BSX has a market cap of 64.5B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while BSX trades at $43.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas BSX's P/E ratio is 14.00. In terms of profitability, PODD's ROE is +0.27%, compared to BSX's ROE of +0.15%. Regarding short-term risk, PODD is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for PODD.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
PODD vs EW Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, EW has a market cap of 50.8B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while EW trades at $88.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas EW's P/E ratio is 32.69. In terms of profitability, PODD's ROE is +0.27%, compared to EW's ROE of +0.10%. Regarding short-term risk, PODD is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for PODD.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
PODD vs DXCM Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, DXCM has a market cap of 33.7B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while DXCM trades at $89.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas DXCM's P/E ratio is 35.04. In terms of profitability, PODD's ROE is +0.27%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, PODD is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for PODD.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
PODD vs GEHC Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, GEHC has a market cap of 29B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while GEHC trades at $64.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas GEHC's P/E ratio is 14.06. In terms of profitability, PODD's ROE is +0.27%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, PODD is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for PODD.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
PODD vs PHG Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, PHG has a market cap of 24.1B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while PHG trades at $24.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas PHG's P/E ratio is 14.10. In terms of profitability, PODD's ROE is +0.27%, compared to PHG's ROE of +0.10%. Regarding short-term risk, PODD is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for PODD.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
PODD vs ZBH Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, ZBH has a market cap of 18.4B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while ZBH trades at $95.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas ZBH's P/E ratio is 11.25. In terms of profitability, PODD's ROE is +0.27%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, PODD is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for PODD.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
PODD vs ABMD Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas ABMD's P/E ratio is 65.36. In terms of profitability, PODD's ROE is +0.27%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, PODD is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for PODD.Check ABMD's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
PODD vs SWAV Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas SWAV's P/E ratio is 78.76. In terms of profitability, PODD's ROE is +0.27%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, PODD is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for PODD.Check SWAV's competition here
Penumbra, Inc. (NYSE: PEN)
PODD vs PEN Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while PEN trades at $317.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas PEN's P/E ratio is 82.93. In terms of profitability, PODD's ROE is +0.27%, compared to PEN's ROE of +0.11%. Regarding short-term risk, PODD is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for PODD.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
PODD vs SNN Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, SNN has a market cap of 11.6B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while SNN trades at $27.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas SNN's P/E ratio is 12.97. In terms of profitability, PODD's ROE is +0.27%, compared to SNN's ROE of +0.12%. Regarding short-term risk, PODD is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for PODD.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
PODD vs ALGN Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, ALGN has a market cap of 10.7B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while ALGN trades at $147.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas ALGN's P/E ratio is 13.65. In terms of profitability, PODD's ROE is +0.27%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, PODD is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for PODD.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
PODD vs BIO-B Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, BIO-B has a market cap of 10.6B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while BIO-B trades at $385.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas BIO-B's P/E ratio is -67.94. In terms of profitability, PODD's ROE is +0.27%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, PODD is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for PODD.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
PODD vs BIO Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, BIO has a market cap of 10.1B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while BIO trades at $376.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas BIO's P/E ratio is 40.53. In terms of profitability, PODD's ROE is +0.27%, compared to BIO's ROE of +0.03%. Regarding short-term risk, PODD is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for PODD.Check BIO's competition here
Globus Medical, Inc. (NYSE: GMED)
PODD vs GMED Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, GMED has a market cap of 10B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while GMED trades at $74.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas GMED's P/E ratio is 16.69. In terms of profitability, PODD's ROE is +0.27%, compared to GMED's ROE of +0.12%. Regarding short-term risk, PODD is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for PODD.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
PODD vs GKOS Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, GKOS has a market cap of 9.7B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while GKOS trades at $163.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas GKOS's P/E ratio is -190.27. In terms of profitability, PODD's ROE is +0.27%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, PODD is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for PODD.Check GKOS's competition here
Masimo Corporation (NASDAQ: MASI)
PODD vs MASI Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas MASI's P/E ratio is 44.43. In terms of profitability, PODD's ROE is +0.27%, compared to MASI's ROE of +0.09%. Regarding short-term risk, PODD is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for PODD.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
PODD vs BRKR Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, BRKR has a market cap of 9.3B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while BRKR trades at $61.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas BRKR's P/E ratio is 30.85. In terms of profitability, PODD's ROE is +0.27%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, PODD is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for PODD.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
PODD vs BRKRP Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, BRKRP has a market cap of 9B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while BRKRP trades at $447.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas BRKRP's P/E ratio is 245.01. In terms of profitability, PODD's ROE is +0.27%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, PODD is less volatile compared to BRKRP. This indicates lower risk in terms of short-term price fluctuations for PODD.Check BRKRP's competition here
Haemonetics Corporation (NYSE: HAE)
PODD vs HAE Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, HAE has a market cap of 4.9B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while HAE trades at $108.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas HAE's P/E ratio is 21.66. In terms of profitability, PODD's ROE is +0.27%, compared to HAE's ROE of +0.11%. Regarding short-term risk, PODD is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for PODD.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
PODD vs NARI Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas NARI's P/E ratio is -59.24. In terms of profitability, PODD's ROE is +0.27%, compared to NARI's ROE of -0.00%. Regarding short-term risk, PODD is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for PODD.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
PODD vs ITGR Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while ITGR trades at $126.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas ITGR's P/E ratio is 19.90. In terms of profitability, PODD's ROE is +0.27%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, PODD is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for PODD.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
PODD vs LIVN Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while LIVN trades at $78.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas LIVN's P/E ratio is 18.53. In terms of profitability, PODD's ROE is +0.27%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, PODD is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for PODD.Check LIVN's competition here
Axonics, Inc. (NASDAQ: AXNX)
PODD vs AXNX Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas AXNX's P/E ratio is -709.80. In terms of profitability, PODD's ROE is +0.27%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, PODD is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for PODD.Check AXNX's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
PODD vs IRTC Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while IRTC trades at $109.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas IRTC's P/E ratio is -254.26. In terms of profitability, PODD's ROE is +0.27%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, PODD is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for PODD.Check IRTC's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
PODD vs TMDX Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, TMDX has a market cap of 3B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while TMDX trades at $86.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas TMDX's P/E ratio is 43.87. In terms of profitability, PODD's ROE is +0.27%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, PODD is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for PODD.Check TMDX's competition here
Neogen Corporation (NASDAQ: NEOG)
PODD vs NEOG Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, NEOG has a market cap of 2.8B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while NEOG trades at $13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas NEOG's P/E ratio is 46.39. In terms of profitability, PODD's ROE is +0.27%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, PODD is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for PODD.Check NEOG's competition here
AxoGen, Inc. (NASDAQ: AXGN)
PODD vs AXGN Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, AXGN has a market cap of 2.4B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while AXGN trades at $44.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas AXGN's P/E ratio is 116.39. In terms of profitability, PODD's ROE is +0.27%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, PODD is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for PODD.Check AXGN's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
PODD vs INSP Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, INSP has a market cap of 2.2B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while INSP trades at $76.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas INSP's P/E ratio is 33.84. In terms of profitability, PODD's ROE is +0.27%, compared to INSP's ROE of +0.18%. Regarding short-term risk, PODD is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for PODD.Check INSP's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
PODD vs UFPT Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, UFPT has a market cap of 2.1B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while UFPT trades at $276.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas UFPT's P/E ratio is 28.26. In terms of profitability, PODD's ROE is +0.27%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, PODD is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for PODD.Check UFPT's competition here
Butterfly Network, Inc. (NYSE: BFLY)
PODD vs BFLY Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, BFLY has a market cap of 2.1B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while BFLY trades at $7.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas BFLY's P/E ratio is -32.81. In terms of profitability, PODD's ROE is +0.27%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, PODD is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for PODD.Check BFLY's competition here
NuVasive, Inc. (NASDAQ: NUVA)
PODD vs NUVA Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas NUVA's P/E ratio is 75.00. In terms of profitability, PODD's ROE is +0.27%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, PODD is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for PODD.Check NUVA's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
PODD vs ESTA Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, ESTA has a market cap of 2B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while ESTA trades at $69.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas ESTA's P/E ratio is -55.00. In terms of profitability, PODD's ROE is +0.27%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, PODD is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for PODD.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
PODD vs NVCR Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while NVCR trades at $16.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas NVCR's P/E ratio is -12.84. In terms of profitability, PODD's ROE is +0.27%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, PODD is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for PODD.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
PODD vs ATEC Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while ATEC trades at $10.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas ATEC's P/E ratio is -169.67. In terms of profitability, PODD's ROE is +0.27%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, PODD is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for PODD.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
PODD vs CNMD Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while CNMD trades at $45.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas CNMD's P/E ratio is 10.00. In terms of profitability, PODD's ROE is +0.27%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, PODD is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for PODD.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
PODD vs HSKA Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas HSKA's P/E ratio is -62.49. In terms of profitability, PODD's ROE is +0.27%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, PODD is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for PODD.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
PODD vs IART Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, IART has a market cap of 1.2B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while IART trades at $15.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas IART's P/E ratio is 6.45. In terms of profitability, PODD's ROE is +0.27%, compared to IART's ROE of -0.01%. Regarding short-term risk, PODD is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for PODD.Check IART's competition here
Avanos Medical, Inc. (NYSE: AVNS)
PODD vs AVNS Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas AVNS's P/E ratio is 27.77. In terms of profitability, PODD's ROE is +0.27%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, PODD is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for PODD.Check AVNS's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
PODD vs TNDM Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while TNDM trades at $16.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas TNDM's P/E ratio is -18.14. In terms of profitability, PODD's ROE is +0.27%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, PODD is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for PODD.Check TNDM's competition here
Artivion, Inc. (NYSE: AORT)
PODD vs AORT Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while AORT trades at $23.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas AORT's P/E ratio is 38.85. In terms of profitability, PODD's ROE is +0.27%, compared to AORT's ROE of -0.01%. Regarding short-term risk, PODD is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for PODD.Check AORT's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
PODD vs SILK Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas SILK's P/E ratio is -18.96. In terms of profitability, PODD's ROE is +0.27%, compared to SILK's ROE of -0.35%. Regarding short-term risk, PODD is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for PODD.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
PODD vs FNA Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas FNA's P/E ratio is -19.83. In terms of profitability, PODD's ROE is +0.27%, compared to FNA's ROE of -0.35%. Regarding short-term risk, PODD is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for PODD.Check FNA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
PODD vs PRCT Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, PRCT has a market cap of 1.1B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while PRCT trades at $19.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas PRCT's P/E ratio is -9.95. In terms of profitability, PODD's ROE is +0.27%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, PODD is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for PODD.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
PODD vs LMRI Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while LMRI trades at $11.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas LMRI's P/E ratio is -21.56. In terms of profitability, PODD's ROE is +0.27%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, PODD is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for PODD.Check LMRI's competition here
IRadimed Corporation (NASDAQ: IRMD)
PODD vs IRMD Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, IRMD has a market cap of 1B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while IRMD trades at $82.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas IRMD's P/E ratio is 41.27. In terms of profitability, PODD's ROE is +0.27%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, PODD is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for PODD.Check IRMD's competition here
Enovis Corporation (NYSE: ENOV)
PODD vs ENOV Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, ENOV has a market cap of 1B. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while ENOV trades at $18.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas ENOV's P/E ratio is 5.17. In terms of profitability, PODD's ROE is +0.27%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, PODD is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for PODD.Check ENOV's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
PODD vs BBNX Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, BBNX has a market cap of 984.8M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while BBNX trades at $21.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas BBNX's P/E ratio is -13.27. In terms of profitability, PODD's ROE is +0.27%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, PODD is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for PODD.Check BBNX's competition here
CeriBell, Inc. (NASDAQ: CBLL)
PODD vs CBLL Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, CBLL has a market cap of 924.7M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while CBLL trades at $24.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas CBLL's P/E ratio is -13.85. In terms of profitability, PODD's ROE is +0.27%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, PODD is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for PODD.Check CBLL's competition here
Bioventus Inc. (NASDAQ: BVS)
PODD vs BVS Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, BVS has a market cap of 874.6M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while BVS trades at $12.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas BVS's P/E ratio is 16.99. In terms of profitability, PODD's ROE is +0.27%, compared to BVS's ROE of +0.28%. Regarding short-term risk, PODD is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for PODD.Check BVS's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
PODD vs CSII Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas CSII's P/E ratio is -20.83. In terms of profitability, PODD's ROE is +0.27%, compared to CSII's ROE of -0.14%. Regarding short-term risk, PODD is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for PODD.Check CSII's competition here
InMode Ltd. (NASDAQ: INMD)
PODD vs INMD Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, INMD has a market cap of 824.8M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while INMD trades at $14.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas INMD's P/E ratio is 9.97. In terms of profitability, PODD's ROE is +0.27%, compared to INMD's ROE of +0.12%. Regarding short-term risk, PODD is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for PODD.Check INMD's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
PODD vs SIBN Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, SIBN has a market cap of 802.3M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while SIBN trades at $18.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas SIBN's P/E ratio is -53.21. In terms of profitability, PODD's ROE is +0.27%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, PODD is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for PODD.Check SIBN's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
PODD vs AVR Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, AVR has a market cap of 793.4M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while AVR trades at $8.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas AVR's P/E ratio is -4.21. In terms of profitability, PODD's ROE is +0.27%, compared to AVR's ROE of -0.78%. Regarding short-term risk, PODD is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for PODD.Check AVR's competition here
Varex Imaging Corporation (NASDAQ: VREX)
PODD vs VREX Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, VREX has a market cap of 778.4M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while VREX trades at $18.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas VREX's P/E ratio is 19.46. In terms of profitability, PODD's ROE is +0.27%, compared to VREX's ROE of +0.05%. Regarding short-term risk, PODD is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for PODD.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
PODD vs AHCO Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, AHCO has a market cap of 776.9M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while AHCO trades at $5.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas AHCO's P/E ratio is 11.65. In terms of profitability, PODD's ROE is +0.27%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, PODD is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for PODD.Check AHCO's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
PODD vs CTKB Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, CTKB has a market cap of 684.5M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while CTKB trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas CTKB's P/E ratio is -28.08. In terms of profitability, PODD's ROE is +0.27%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, PODD is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for PODD.Check CTKB's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
PODD vs SSII Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, SSII has a market cap of 652.4M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while SSII trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas SSII's P/E ratio is -63.58. In terms of profitability, PODD's ROE is +0.27%, compared to SSII's ROE of -0.27%. Regarding short-term risk, PODD is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for PODD.Check SSII's competition here
Surmodics, Inc. (NASDAQ: SRDX)
PODD vs SRDX Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas SRDX's P/E ratio is -34.66. In terms of profitability, PODD's ROE is +0.27%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, PODD is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for PODD.Check SRDX's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
PODD vs APEN Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas APEN's P/E ratio is -9.43. In terms of profitability, PODD's ROE is +0.27%, compared to APEN's ROE of -0.85%. Regarding short-term risk, PODD is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for PODD.Check APEN's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
PODD vs KIDS Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, KIDS has a market cap of 560.4M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while KIDS trades at $21.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas KIDS's P/E ratio is -18.49. In terms of profitability, PODD's ROE is +0.27%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, PODD is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for PODD.Check KIDS's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
PODD vs DCTH Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, DCTH has a market cap of 556.1M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while DCTH trades at $16.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas DCTH's P/E ratio is 1611.00. In terms of profitability, PODD's ROE is +0.27%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, PODD is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for PODD.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
PODD vs ZIMV Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, PODD's ROE is +0.27%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, PODD is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for PODD.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
PODD vs CERS Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, CERS has a market cap of 534M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while CERS trades at $2.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas CERS's P/E ratio is -52.89. In terms of profitability, PODD's ROE is +0.27%, compared to CERS's ROE of -0.10%. Regarding short-term risk, PODD is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for PODD.Check CERS's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
PODD vs TCMD Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, TCMD has a market cap of 500.7M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while TCMD trades at $22.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas TCMD's P/E ratio is 20.56. In terms of profitability, PODD's ROE is +0.27%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, PODD is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for PODD.Check TCMD's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
PODD vs NPCE Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, NPCE has a market cap of 486.9M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while NPCE trades at $14.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas NPCE's P/E ratio is -25.05. In terms of profitability, PODD's ROE is +0.27%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, PODD is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for PODD.Check NPCE's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
PODD vs SGHT Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, SGHT has a market cap of 436.4M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while SGHT trades at $8.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas SGHT's P/E ratio is -14.32. In terms of profitability, PODD's ROE is +0.27%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, PODD is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for PODD.Check SGHT's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
PODD vs PACB Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, PACB has a market cap of 425.5M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while PACB trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas PACB's P/E ratio is -3.34. In terms of profitability, PODD's ROE is +0.27%, compared to PACB's ROE of -49.62%. Regarding short-term risk, PODD is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for PODD.Check PACB's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
PODD vs CLPT Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, CLPT has a market cap of 414.8M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while CLPT trades at $13.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas CLPT's P/E ratio is -11.72. In terms of profitability, PODD's ROE is +0.27%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, PODD is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for PODD.Check CLPT's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
PODD vs SENS Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, SENS has a market cap of 400.4M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while SENS trades at $9.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas SENS's P/E ratio is -4.30. In terms of profitability, PODD's ROE is +0.27%, compared to SENS's ROE of -1.66%. Regarding short-term risk, PODD is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for PODD.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
PODD vs OFIX Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, OFIX has a market cap of 352.1M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while OFIX trades at $8.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas OFIX's P/E ratio is -5.67. In terms of profitability, PODD's ROE is +0.27%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, PODD is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for PODD.Check OFIX's competition here
CapsoVision, Inc. (NASDAQ: CV)
PODD vs CV Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, CV has a market cap of 334.8M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while CV trades at $6.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas CV's P/E ratio is -10.63. In terms of profitability, PODD's ROE is +0.27%, compared to CV's ROE of -1.78%. Regarding short-term risk, PODD is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for PODD.Check CV's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
PODD vs CATX Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, CATX has a market cap of 327.3M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while CATX trades at $2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas CATX's P/E ratio is -2.16. In terms of profitability, PODD's ROE is +0.27%, compared to CATX's ROE of -0.42%. Regarding short-term risk, PODD is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for PODD.Check CATX's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
PODD vs TLSI Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, TLSI has a market cap of 314M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while TLSI trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas TLSI's P/E ratio is -3.04. In terms of profitability, PODD's ROE is +0.27%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, PODD is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for PODD.Check TLSI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
PODD vs SMLR Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas SMLR's P/E ratio is 3.92. In terms of profitability, PODD's ROE is +0.27%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, PODD is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for PODD.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
PODD vs TMCI Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, TMCI has a market cap of 291.3M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while TMCI trades at $4.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas TMCI's P/E ratio is -4.78. In terms of profitability, PODD's ROE is +0.27%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, PODD is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for PODD.Check TMCI's competition here
Avita Medical Inc. (NASDAQ: RCEL)
PODD vs RCEL Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, RCEL has a market cap of 273.8M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while RCEL trades at $11.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas RCEL's P/E ratio is -7.65. In terms of profitability, PODD's ROE is +0.27%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, PODD is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for PODD.Check RCEL's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
PODD vs INFU Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, INFU has a market cap of 258.3M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while INFU trades at $12.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas INFU's P/E ratio is 31.22. In terms of profitability, PODD's ROE is +0.27%, compared to INFU's ROE of +0.15%. Regarding short-term risk, PODD is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for PODD.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
PODD vs MGRM Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas MGRM's P/E ratio is -12.00. In terms of profitability, PODD's ROE is +0.27%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, PODD is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for PODD.Check MGRM's competition here
Nevro Corp. (NYSE: NVRO)
PODD vs NVRO Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas NVRO's P/E ratio is -1.91. In terms of profitability, PODD's ROE is +0.27%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, PODD is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for PODD.Check NVRO's competition here
Electromed, Inc. (AMEX: ELMD)
PODD vs ELMD Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, ELMD has a market cap of 218.5M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while ELMD trades at $26.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas ELMD's P/E ratio is 20.15. In terms of profitability, PODD's ROE is +0.27%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, PODD is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for PODD.Check ELMD's competition here
RxSight, Inc. (NASDAQ: RXST)
PODD vs RXST Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, RXST has a market cap of 215.3M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while RXST trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas RXST's P/E ratio is -4.60. In terms of profitability, PODD's ROE is +0.27%, compared to RXST's ROE of -0.17%. Regarding short-term risk, PODD is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for PODD.Check RXST's competition here
Profound Medical Corp. (NASDAQ: PROF)
PODD vs PROF Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, PROF has a market cap of 212.9M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while PROF trades at $5.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas PROF's P/E ratio is -5.98. In terms of profitability, PODD's ROE is +0.27%, compared to PROF's ROE of -0.56%. Regarding short-term risk, PODD is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for PODD.Check PROF's competition here
Neuronetics, Inc. (NASDAQ: STIM)
PODD vs STIM Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, STIM has a market cap of 201.8M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while STIM trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas STIM's P/E ratio is -6.59. In terms of profitability, PODD's ROE is +0.27%, compared to STIM's ROE of -1.51%. Regarding short-term risk, PODD is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for PODD.Check STIM's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
PODD vs BSGM Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas BSGM's P/E ratio is -5.81. In terms of profitability, PODD's ROE is +0.27%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, PODD is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for PODD.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
PODD vs MDGS Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas MDGS's P/E ratio is -0.27. In terms of profitability, PODD's ROE is +0.27%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, PODD is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for PODD.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
PODD vs QIPT Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas QIPT's P/E ratio is -15.87. In terms of profitability, PODD's ROE is +0.27%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, PODD is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for PODD.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
PODD vs FOCL Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, FOCL has a market cap of 155.6M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while FOCL trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas FOCL's P/E ratio is -4.01. In terms of profitability, PODD's ROE is +0.27%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, PODD is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for PODD.Check FOCL's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
PODD vs LUCD Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, LUCD has a market cap of 149.9M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while LUCD trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas LUCD's P/E ratio is -2.12. In terms of profitability, PODD's ROE is +0.27%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, PODD is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for PODD.Check LUCD's competition here
Quantum-Si incorporated (NASDAQ: QSI)
PODD vs QSI Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, QSI has a market cap of 147.4M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while QSI trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas QSI's P/E ratio is -1.62. In terms of profitability, PODD's ROE is +0.27%, compared to QSI's ROE of -0.47%. Regarding short-term risk, PODD is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for PODD.Check QSI's competition here
Quanterix Corporation (NASDAQ: QTRX)
PODD vs QTRX Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, QTRX has a market cap of 144.6M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while QTRX trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas QTRX's P/E ratio is -1.21. In terms of profitability, PODD's ROE is +0.27%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, PODD is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for PODD.Check QTRX's competition here
Inogen, Inc. (NASDAQ: INGN)
PODD vs INGN Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, INGN has a market cap of 139.2M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while INGN trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas INGN's P/E ratio is -5.65. In terms of profitability, PODD's ROE is +0.27%, compared to INGN's ROE of -0.13%. Regarding short-term risk, PODD is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for PODD.Check INGN's competition here
iCAD, Inc. (NASDAQ: ICAD)
PODD vs ICAD Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas ICAD's P/E ratio is -20.37. In terms of profitability, PODD's ROE is +0.27%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, PODD is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for PODD.Check ICAD's competition here
electroCore, Inc. (NASDAQ: ECOR)
PODD vs ECOR Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, ECOR has a market cap of 105.3M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while ECOR trades at $11.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas ECOR's P/E ratio is -6.95. In terms of profitability, PODD's ROE is +0.27%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, PODD is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for PODD.Check ECOR's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
PODD vs HJLI Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas HJLI's P/E ratio is N/A. In terms of profitability, PODD's ROE is +0.27%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, PODD is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for PODD.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
PODD vs ASXC Comparison September 2026
Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PODD stands at 9.7B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, PODD is priced at $140.60 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PODD currently has a P/E ratio of 23.95, whereas ASXC's P/E ratio is -1.12. In terms of profitability, PODD's ROE is +0.27%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, PODD is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for PODD.Check ASXC's competition here